Skip to content

免疫万特

US · IMVT #1790 按市值排名 上市于 2017
26.73 -0.78 -2.84%
实时 - 追踪5344个代码 - 心跳于503秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

涨跌不一/平稳
  • 最近一期（2026/Q3）披露持股的机构数量增加了1家。
  • 机构持股总比例基本持平。

机构持股

机构持股比例
108.75% -0.02pp
机构数量
265 +1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Public Company56.95%
Mutual Fund28.51%
Hedge Fund14.47%
VC/PE Fund7.46%
Private Company0.98%
Individual/Insider0.70%
Insurance Company0.19%
Government Pension Fund0.15%

主要股东 截至 2025-12-12

Roivant Sciences Ltd. 54.86% · 113.32M 股
FMR 7.83% · 16.17M 股
Deep Track Capital, LP 4.52% · 9.34M 股
BlackRock 3.48% · 7.18M 股
Farallon Capital Management, L.L.C. 2.81% · 5.81M 股
Baker Bros. Advisors LP 2.63% · 5.44M 股
State Street Global Advisors 2.24% · 4.62M 股
TCG Crossover Management, LLC 2.16% · 4.46M 股
Vanguard Capital Management, LLC 2.03% · 4.20M 股
T. Rowe Price Group, Inc. 1.96% · 4.05M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 23次买入 · 27次卖出

姓名职务持股比例
Roivant Sciences Ltd. -- 54.86%
Peter Salzmann Chief Executive Officer 0.30%
William Macias Chief Medical Officer 0.10%
Eva Barnett Chief Financial Officer 0.08%
Atul Pande Independent Director 0.05%
Michael Geffner Chief Medical Officer 0.04%
Douglas Hughes Independent Director 0.03%
Jay Stout Chief Technology Officer 0.02%
Christopher Van Tuyl Chief Legal Officer 0.02%
Tiago Girao Chief Financial Officer 0.02%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-22 Christopher Van Tuyl Chief Legal Officer Open Market Disposition -2,846 $36.36
2026-08-27 Atul Pande Independent Director Derivative Exercise and Sale -1,500 $8.43–43.27
2026-08-19 Melanie Gloria Chief Operating Officer Open Market Disposition -3,056 $44.16
2026-07-23 Atul Pande Independent Director Derivative Exercise and Sale -1,500 $8.43–39.80
2026-07-22 Tiago Girao Chief Financial Officer Open Market Disposition -6,798 $38.69
2026-07-22 Jay Stout Chief Technology Officer Open Market Disposition -2,857 $38.69
2026-07-07 Christopher Van Tuyl Chief Legal Officer Open Market Disposition -1,206 $39.53–39.99
2026-07-07 Melanie Gloria Chief Operating Officer Open Market Disposition -2,036 $39.53–39.99
2026-07-07 Jay Stout Chief Technology Officer Open Market Disposition -3,487 $39.53–39.99
2026-07-01 Eric Venker Director Derivative Exercise and Sale -89,721 $14.46–38.48
2026-06-30 Eric Venker Director Derivative Exercise and Retained +2,467 $14.46
2026-06-25 Atul Pande Independent Director Derivative Exercise and Sale -1,500 $8.43–38.01
2026-06-25 Christopher Van Tuyl Chief Legal Officer Derivative Exercise and Sale -17,824 $15.20–38.96
2026-06-25 Tiago Girao Chief Financial Officer Derivative Exercise and Sale -10,000 $15.90–38.46
2026-06-25 Melanie Gloria Chief Operating Officer Open Market Disposition -17,714 $38.18–38.95
2026-06-25 Jay Stout Chief Technology Officer Open Market Disposition -40,000 $38.18–38.94
2026-06-17 Christopher Van Tuyl Chief Legal Officer Open Market Disposition -2,634 $35.39
2026-06-14 Atul Pande Independent Director Derivative Exercise and Sale -1,500 $8.43–34.02
2026-05-27 Andrew Fromkin Director Open Market Disposition -25,350 $33.56
2026-05-27 Andrew Fromkin Director Derivative Exercise and Sale -196,601 $4.99–33.56

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:15 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

免疫万特 讨论区 0 条评论

发表评论